Source comparison
Side Effect Profiles: Short-Term Relief vs Long-Term Risk
Repeated cortisone injections. Especially in weight-bearing tendons like the Achilles, patellar tendon, or rotator cuff. Carry documented risks of tissue weakening and rupture. A systematic review published in Clinical Orthopaedics and Related Research found t
This comparison does not assign a generated winner or score.
- Repeated cortisone injections. Especially in weight-bearing tendons like the Achilles, patellar tendon, or rotator cuff. Carry documented risks of tissue weakening and rupture. A systematic review published in Clinical Orthopaedics and Related Research found that corticosteroid injections administered more than three times to the same site increased tendon rupture risk by 3.7-fold compared to no injection. The mechanism is clear: glucocorticoids inhibit fibroblast activity and collagen synthesis, which are essential for maintaining tendon tensile strength. Cortisone also causes localized tissue atrophy when used repeatedly, a condition called steroid-induced tendon degeneration.
- BPC-157 differs from cortisone injections in its safety profile. Preclinical data across multiple animal models (rats, rabbits) has shown no systemic toxicity, no organ damage, and no immune suppression even at doses 10–100 times higher than therapeutic ranges. Human data remains limited. BPC-157 is classified as a research peptide, not an FDA-approved drug. But anecdotal reports from compounding pharmacy use and underground athletic circles suggest minimal adverse effects beyond occasional injection site soreness. There are no reports of tissue weakening or structural degradation associated with BPC-157 use.
- Our experience working with researchers in this space shows a consistent pattern: cortisone provides faster symptom relief (24–72 hours) but carries structural risks with repeated use. BPC-157 requires patience. Noticeable improvement typically takes 7–14 days. But doesn't compromise tissue integrity. For acute inflammatory flares, cortisone makes sense. For chronic tendinopathy or partial tears where long-term healing is the goal, BPC-157 is the mechanistically superior option.